Staffan Lindstrand

Aerocrine AB operates as a specialty pharmaceutical company focused on respiratory disease. The company was founded by Lars E. Gustafsson, Jon Lundberg, Kjell Alving, and Eddie Weitzberg in November 1997 and is headquartered in Uppsala, Sweden.

Inion Oy is a medical devices company focused on the development and commercialization of innovative biodegradable and bioactive implants for applications in Spine and Specialty Orthopedics applications. By targeting key strategic markets in the USA and select territories in the rest of the world, Inion has built a product portfolio sold through a dedicated network of specialist distributors. Inion's products include biodegradable plates, screws, pins and membranes, which are used to enhance the healing of bone or soft tissue injuries, such as those caused by trauma or by reconstructive surgery. Inion's core expertise is in the design and manufacture of implants from its proprietary Inion Optima™ family of biomaterials, which enables the Company to develop medical implants with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation. Incorporated in 2000, Inion has offices in the UK and USA, and its head office, R&D and manufacturing facilities are in Tampere, Finland.

HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland.

Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase.

Newron Sweden AB is a biopharmaceutical company engaged in the development of novel therapies for the treatment of disorders of the central nervous systems. The company was founded by Jonas Cristopher Frisen and Ann Marie Janson in 1998 and is headquartered in Stockholm, Sweden.

Creative Peptides Sweden AB develops and manufactures drugs. The company discovers and develops biopharmaceutical drugs to treat complications of Type 1 diabetes. It was founded in 1996 and is headquartered in Stockholm, Sweden.